Amylyx Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $87.4M | $380.8M | $22.2M | $285,000 |
| Cost of revenue | $0 | $6.0M | $25.4M | $3.0M | — |
| Selling, general & administrative | $62.9M | $114.3M | $188.4M | $127.1M | $38.9M |
| Research and development | $90.4M | $104.1M | $128.2M | $93.5M | $44.0M |
| Operating income | -$153.3M | -$314.7M | $38.8M | -$201.3M | -$82.7M |
| Pretax income | -$144.7M | -$302.1M | $54.3M | -$197.6M | -$87.9M |
| Income tax expense | $46,000 | -$393,000 | $5.0M | $774,000 | — |
| Net income | -$144.7M | -$301.7M | $49.3M | -$198.4M | -$87.9M |
| Balance Sheet | |||||
| Cash and equivalents | $226.7M | $77.4M | $170.2M | $62.5M | $50.2M |
| Current assets | $323.7M | $189.4M | $464.7M | $382.1M | $105.0M |
| Total assets | $332.6M | $193.6M | $517.5M | $391.5M | $105.6M |
| Current liabilities | $22.7M | $28.4M | $82.0M | $46.6M | $17.4M |
| Total liabilities | $27.4M | $28.9M | $84.0M | $50.8M | $17.4M |
| Stockholders' equity | $305.3M | $164.8M | $433.4M | $340.6M | -$151.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$123.3M | -$167.6M | $11.9M | -$179.9M | -$74.8M |
| Depreciation and amortization | $525,000 | $904,000 | $1.1M | $487,000 | $52,000 |
| Stock-based compensation | $27.6M | $33.0M | $37.2M | $21.7M | $3.1M |
| Capital expenditure | $138,000 | $157,000 | $1.2M | $2.5M | $353,000 |
| Free cash flow | -$123.5M | -$167.8M | $10.7M | -$182.4M | -$75.2M |
| Impairments | — | $958,000 | $0 | $0 | $0 |
Shares outstanding 111.2M · Free float 79.8%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.